Jazz Pharmaceuticals PLC (JAZZ)
| Market Cap | 8.84B |
| Revenue (ttm) | 2.63B |
| Net Income (ttm) | 40.16M |
| Shares Out | 61.36M |
| EPS (ttm) | 0.69 |
| PE Ratio | 209.51 |
| Forward PE | 7.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,601 |
| Open | 145.10 |
| Previous Close | 145.67 |
| Day's Range | 143.00 - 146.42 |
| 52-Week Range | 126.01 - 189.00 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 205.47 (+42.5%) |
| Est. Earnings Date | Nov 1, 2021 |
About JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narc...
Financial Performance
In 2020, JAZZ's revenue was $2.36 billion, an increase of 9.34% compared to the previous year's $2.16 billion. Earnings were $238.62 million, a decrease of -54.41%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is 205.47, which is an increase of 42.55% from the latest price.
News
Best Marijuana Stocks To Watch For Your Long Term Portfolio Right Now
Is Now The Time To Add To Your Long Term Portfolio? The post Best Marijuana Stocks To Watch For Your Long Term Portfolio Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roo...
SEC Charges Former Goldman Sachs Officer For Insider Trading On 2 M&A Deals
The Securities and Exchange Commission has charged a former Goldman Sachs (NYSE: GS) compliance analyst with using confidential information to generate over $471,000 in ill-gotten gains. The suit allege...
September Sell-Off: 3 Dirt Cheap Growth Stocks to Buy
Get these stocks while they're near their 52-week lows.
Are These 2 Top Cannabis Stocks On Your List For September? 2 To Watch For Your Long Term Portfolio
Top Cannabis Stocks To Watch Mid-September The post Are These 2 Top Cannabis Stocks On Your List For September? 2 To Watch For Your Long Term Portfolio appeared first on Marijuana Stocks | Cannabis Inve...
Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on Octobe...
DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m.
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
DUBLIN, Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences: BofA Virtual Globa...
2 Marijuana Stocks To Watch At The Beginning Of September 2021
2 Marijuana Stocks To Watch This Month For Better Trading The post 2 Marijuana Stocks To Watch At The Beginning Of September 2021 appeared first on Marijuana Stocks | Cannabis Investments and News. Root...
3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023
These fast-paced companies should generate jaw-dropping revenue growth over the next three years.
Jazz (JAZZ) Down 14.1% Since Last Earnings Report: Can It Rebound?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
3 Biotech Stocks That Are Too Cheap to Ignore
You'll definitely want to check out these biotech bargains.
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – ...
Canada Approves Jazz Pharma's Excessive Daytime Sleepiness Med
Health Canada has approved Jazz Pharmaceuticals plc's (NASDAQ: JAZZ) Sunosi (solriamfetol) for excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) in adult pat...
Got $4,000? Buy These 2 Cannabis-Focused Biotech Stocks
Neither of them needs to sell marijuana to consumers to succeed.
The Smartest Stocks to Buy With $600 Right Now
Bargains abound, even with the stock market near an all-time high.
Best Medical Marijuana Stocks To Buy In 2021? 2 Possible Long Term Investments Right Now
Could These Be Good Long Term Investments For Your Portfolio? The post Best Medical Marijuana Stocks To Buy In 2021? 2 Possible Long Term Investments Right Now appeared first on Marijuana Stocks | Canna...
This Cannabis Stock Is Full of Potential and Hasn't Been This Cheap in Months
Investors have been selling off the stock since the company released its earnings report earlier this month.
A Week's Worth of Actionable Cannabis Stock News
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up...
Jazz's (JAZZ) Xywav Gets FDA Nod for Idiopathic Hypersomnia
Jazz's (JAZZ) Xywav gets FDA approval for new indication, idiopathic hypersomnia. Following approval, Xywav becomes the first drug for treatment of this sleep disorder.
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral ...
DUBLIN, Aug. 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav® (calcium, magnesium, potassium, and sodium ...
Jazz's (JAZZ) Epidyolex Gets Approval for New Indication in UK
Jazz's (JAZZ) unit GW Pharmaceuticals' Epidyolex (cannabidiol) gets a regulatory nod for a new indication in the United Kingdom. Following this announcement, stock prices fell.
Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers
LOS ANGELES, Aug. 10, 2021 /PRNewswire/ -- Stand Up To Cancer® (SU2C) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announce a three-year, $4 million research collaboration to explore new opportunit...
GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associa...
LONDON, Aug. 10, 2021 /PRNewswire/ -- GW Pharmaceuticals ("GW"), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines and now part of Jazz Pharmaceutical...
Your Weekly Hit of Cannabis Stocks on the Move
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up...
Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout
Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.
Jazz Pharmaceuticals (JAZZ) Tops Q2 Earnings and Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of 9.86% and 1.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?